Original Publication Date: 1 June, 2016
Publication / Source: Future Oncology
Authors: Hampig Raphael Kourie, Samer Tabchi & Joseph Kattan
The dawn of the past century saw the exploitation of radiation therapy in Hodgkin lymphoma (HL) and its ensuing cures in some of the treated patients. Subsequent developments in the study of malignant diseases, and an improved understanding of lymphoma growth, led to the discernment that a tailored approach is warranted in patients with HL. As such, this type of lymphoma is one of the most curable malignancies nowadays, with a 5-year overall survival exceeding 80% for all stages combined .